Emily M. Leproust Sells 546 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 546 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $24,892.14. Following the completion of the transaction, the chief executive officer now directly owns 672,518 shares in the company, valued at approximately $30,660,095.62. The trade was a 0.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $45.12 on Friday. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a market capitalization of $2.68 billion, a PE ratio of -12.53 and a beta of 1.85. The business’s fifty day moving average price is $46.26 and its two-hundred day moving average price is $46.47.

Analyst Upgrades and Downgrades

TWST has been the topic of several recent analyst reports. Scotiabank upped their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

Institutional Trading of Twist Bioscience

Hedge funds have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience in the third quarter valued at approximately $34,000. Signaturefd LLC increased its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience during the 2nd quarter valued at $61,000. Beaird Harris Wealth Management LLC acquired a new position in Twist Bioscience during the 3rd quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.